OMT-111

MetiMedi Pharmaceuticals · Phase 2 active Small molecule

At a glance

Generic name	OMT-111
Also known as	OMT-110
Sponsor	MetiMedi Pharmaceuticals
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

OMT-111 for Terminal Stage Solid Tumors (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

OMT-111 CI brief — competitive landscape report
OMT-111 updates RSS · CI watch RSS
MetiMedi Pharmaceuticals portfolio CI